Universität zu Köln

Cernak, M. and Nogova, L. (2016). Current antiangiogenic agents in oncology and ophthalmology. Neoplasma, 63 (1). S. 10 - 18. BRATISLAVA: AEPRESS SRO. ISSN 1338-4317

Full text not available from this repository.

Abstract

Antiangiogenic drugs are approved for many cancer types for longer than a decade. Furthermore, several antiangiogenic agents are approved for local application in ophthalmology for treatment of macular degeneration, venous retinal occlusion and diabetic retinopathy. Knowing that antiangiogenic agents are active in ocular system, we reviewed the current literature, whether antiangiogenic drugs may cause ocular side effects in cancer patients by systemic application. Furthermore, we searched in published papers, if systemic application of antiangiogenic agents in cancer patients may simultaneously treat their ocular disorders, if they have such. Finally, we emphasized cooperation between an oncologist and ophthalmologist when treating patients with antiangiogenic drugs.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Cernak, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Nogova, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-293157
DOI:	10.4149/neo_2016_001
Journal or Publication Title:	Neoplasma
Volume:	63
Number:	1
Page Range:	S. 10 - 18
Date:	2016
Publisher:	AEPRESS SRO
Place of Publication:	BRATISLAVA
ISSN:	1338-4317
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language RENAL-CELL CARCINOMA; BEVACIZUMAB AVASTIN THERAPY; ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED PHASE-III; DOUBLE-BLIND; INTRAVITREAL BEVACIZUMAB; MACULAR DEGENERATION; OCULAR TOXICITY; TYROSINE KINASE; SORAFENIB Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/29315